BioMarin Pharmaceutical (BMRN) said Friday it will acquire Amicus Therapeutics (FOLD) for $4.8 billion in a deal that adds two rare disease drugs to its portfolio. In premarket trades on the stock market today, Amicus stock catapulted 29.8% to 14.13, just under the takeover price of $14.50 per share. The biotech stock is highly rated and has climbed roughly 94%…
The FDA's late 2025 approval of hydrogen peroxide as a direct food additive for multiple uses, including as an antimicrobial...
IonQ (IONQ) is highlighted as the most attractive for its advanced commercial traction and direct focus on quantum, while IBM...
Russian President Vladimir Putin on Saturday voiced confidence of victory in Ukraine as he oversaw a military parade on Red Square commemorating...
Key Points Interested in Accel Entertainment, Inc.? Here are five stocks we like better. Accel Entertainment shareholders elected all six...
On September 12, 2015, more than three dozen health experts and diplomats assembled at the Palais des Nations, the United...
Quick Read Ford (F) CEO Jim Farley has signaled a new focus on affordability. This likely means simpler trims, more...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
